When asked about the company's finances, Lanphier said Sangamo is cash-flow positive and is very well financed thanks to its strong partnerships.
Lanphier continued that Sangamo's platform will allow for many treatments to be developed, which is why the company plans for an additional four programs to be trials before the end of the year.
Cramer said that while speculative, Sangamo is still an exciting story, and one than can cure a lot of diseases if it's successful.
Executive Decision: Michael Ward
Lightning RoundIn the Lightning Round, Cramer was bullish on DuPont (DD), Whole Foods Markets (WFM), Lockheed Martin (LMT) and Huntington Ingalls (HII). Cramer was bearish on GT Advanced Technologies (GTAT), SunEdison (SUNE) and Incyte (INCY).
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts